SHIH-HUNG YANGJHE-CYUAN GUOCHIUN HSUSUNG-HSIN KUOYU-WEN TIENANN-LII CHENGKUN-HUEI YEH2020-02-202020-02-2020200929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062360752&doi=10.1016%2fj.jfma.2019.01.015&partnerID=40&md5=1c5abdad45b0b6039e97da9a72107225https://scholars.lib.ntu.edu.tw/handle/123456789/461816Background: Heavily pretreated pancreatic cancer patients have a grave prognosis. In this case series study, we evaluated the safety and efficacy of nab-paclitaxel-based chemotherapy for such patients. Methods: The data of pancreatic adenocarcinoma patients (n = 40) treated with nab-paclitaxel after the failure of gemcitabine or fluoropyrimidines at our institution in 2013–2015 were reviewed. Results: The median number of prior chemotherapy regimens was two (range, 1–6). Eighteen patients had an Eastern Cooperative Oncology Group performance status of ?2. The regimens comprised nab-paclitaxel combined with the following drugs: gemcitabine (n = 28), gemcitabine and fluoropyrimidine (n = 3), platinum and fluoropyrimidine (n = 4), fluoropyrimidine (n = 4), and irinotecan and fluoropyrimidine (n = 1). The median dose of nab-paclitaxel was 63 (range, 51–72) mg/m2/dose, with the schedule of D1/15, D1/8, and D1/8/15 followed in 23, 14, and 3 patients, respectively. The median overall survival was 5.1 (95% CI, 4.6–5.7) months. Among 32 evaluable patients, two partial responses and six stable diseases were observed. The median progression-free survival was 2.6 (95% CI, 1.9–3.2) months. Grade 3/4 leucopenia or neutropenia was observed in three and two patients, respectively. Grade 3/4 anemia was observed in four patients. Other significant (grade 3 or more) nonhematological toxicities were not frequent, except for sepsis/infection (n = 7). However, more severe anemia or sepsis/infection was significantly associated with disease control. Conclusion: In heavily pretreated pancreatic adenocarcinoma patients, low-dose nab-paclitaxel-based chemotherapy was fairly tolerable with modest efficacy. ? 2019[SDGs]SDG3antineoplastic metal complex; CA 19-9 antigen; carcinoembryonic antigen; fluoropyrimidine; gemcitabine; granulocyte colony stimulating factor; irinotecan; paclitaxel; 130-nm albumin-bound paclitaxel; albuminoid; antineoplastic agent; paclitaxel; adjuvant chemotherapy; adult; aged; anemia; Article; cancer combination chemotherapy; cancer survival; clinical article; disease exacerbation; drug efficacy; drug safety; female; human; infection; leukopenia; low drug dose; lymph node metastasis; male; neutropenia; overall survival; pancreas adenocarcinoma; patient history of chemotherapy; peritoneum metastasis; progression free survival; recurrence free survival; sepsis; adenocarcinoma; cancer staging; maximum tolerated dose; middle aged; pancreas tumor; pathology; prognosis; survival analysis; Taiwan; very elderly; young adult; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Survival Analysis; Taiwan; Young Adultjournal article10.1016/j.jfma.2019.01.015308520032-s2.0-85062360752